Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07643610

BEAT-SHOCK Registry

This regulation defines the purpose, the operational processes, and the organization of the registry BEAT-SHOCK (Basel Evaluation of Acute Therapy in cardiogenic SHOCK). It describes the requirements for collecting, storing, processing, managing and sharing health-related registry data.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital Basel

Basel, Canton of Basel-City, 4031, Switzerland

Location status: Recruiting

Location contact

Gregor Leibundgut, Prof. Dr. med.

CONTACT

[email protected]

Gregor Leibundgut, Prof. Dr. med.

PRINCIPAL_INVESTIGATOR

Jasper Boeddinghaus, PD Dr. med.

CONTACT

[email protected]

0041613287897

Jasper Boeddinghaus, PD Dr. med.

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

  • Patients admitted with cardiogenic shock to the University hospital Basel (diagnosis at the time of admission) or development of cardiogenic shock during the hospital stay
  • Age ≥18 years
  • Provision of written ICF
  • Clinical diagnosis of cardiogenic shock.
  • impaired organ perfusion due to primary cardiac dysfunction,
  • persistent systolic blood pressure (SBP) <90 mmHg for ≥30 minutes, or the need for vasopressors, inotropes, or mechanical circulatory support (MCS) to maintain adequate perfusion and
  • evidence of systemic hypoperfusion with arterial lactate ≥2 mmol/L or venous lactate ≥3 mmol/l and ≥1 of the following:
  • Cold or clammy extremities
  • Altered mental status
  • Reduced urine output
  • Signs of volume overload or congestion (on clinical exam, imaging, or invasive monitoring)
  • Patients with normotensive cardiogenic shock (SBP ≥90 mmHg without vasopressors or MCS) may also be included if clear signs of hypoperfusion (arterial lactate ≥2 mmol/L or venous lactate ≥3 mmol/l) and cardiac dysfunction are present and alternative causes are excluded

Exclusion criteria

  • Age <18 years
  • Refusal to provide informed consent by the patient or their legally authorized representative

Treatment and study plan

NO internvention

Other

This is a health data registry.

Primary outcomes

  1. In-Hospital all-cause mortality occurring before discharge from the participating study centre

    Time frame: 10 years

    In-hospital all-cause mortality is defined as death occurring before discharge from the participating study centre. Deaths occurring after transfer to an external hospital are not counted as in-hospital deaths, but are captured through follow-up for 30-day and 90-day mortality.

Secondary outcomes

  1. 30-day and 90-day all-cause Mortality

    Time frame: 30, 90 days

    30-day and 90-day all-cause mortality occuring after discharge from the participating study centre.

  2. Need for organ support at any time during hospitalization

    Time frame: 30, 60, 360 days

    The need for organ support at any time during hospitalization (including renal replacement therapy, mechanical circulation support irrespective of type, and vasoactive or inotropic therapy)

  3. Acute kidney injury (AKI) within 36 hours after index diagnosis of cardiogenic shock/index presentation

    Time frame: Within 36 hours after index diagnosis of cardiogenic shock/ index presentation.

    Occurence of AKI (defined as an increase in serum creatinine of at least 26 µmol/L (0.3 mg/dL)

Study contacts

Contact information is provided by the study sponsor or research team.

Gregor Leibundgut, Prof. Dr.

CONTACT

[email protected]

0041613287897

Jasper Boeddinghaus, PD Dr. med.

CONTACT

[email protected]

0041613287897

Sponsors and collaborators

Lead sponsor

University Hospital, Basel, Switzerland

Other

Registry information

Official study title

BEAT-SHOCK (Basel Evaluation of Acute Therapy in Cardiogenic SHOCK) Registry

Acronym: BEAT-SHOCK

Important dates

Study start
2025
Primary completion
2035
Study completion
2035
First posted
Jun 11, 2026
Registry last updated
Jun 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.